key: cord-1006712-lp8342pn authors: Boyd, Karen; Parcell, Benjamin; Tauro, Sudhir title: Immunosuppression in hematological cancer patients with Covid-19 – uncomplicated infections but delayed viral clearance? date: 2020-06-30 journal: Leuk Res DOI: 10.1016/j.leukres.2020.106407 sha: eeeb89bdf0bdf80f0593493acce6cf23370c4d2f doc_id: 1006712 cord_uid: lp8342pn nan A higher complication rate of Covid-19 infections in hematological malignancies, as a result of compromised immune responses associated with disease or therapy has been suggested. [1] Indeed, from the outset of the pandemic, and prior to the publication of these data [1] , changes to drug schedules and life-style, to reduce risk have been recommended by disease-expert groups (https://b-s-h.org.uk/aboutus/news/covid-19-updates). While several factors including the potential for contracting or transmitting infection during hospital visits and challenges in delivery of care have influenced these recommendations, a significant driver for change has been the perceived level of immunosuppression in patients with hematological cancers. The J o u r n a l P r e -p r o o f scientific rationale for these recommendations is sound, but emerging data indicate that the frequency of Covid-19 complications in patients on immunosuppression for autoimmune disorders is not different from the baseline population. [2, 3] Recent reports on cancer patients including hematological malignancies too suggest that anticancer therapies are unlikely to worsen Covid-19 infections. [4, 5] . The urgency of data reporting has however resulted in these reports lacking treatment details, [5] Data on 4 patients with Covid-19 infection were reviewed. Part of the dataset was submitted to the UK Coronavirus Cancer Monitoring Project. [5] Two outpatients presented with low-grade fever and two (Patients 3 and 4) tested 'positive' during inpatient screening. All patients were in complete remission prior to Covid-19 detection from combined nasal and pharyngeal swabs. Following nucleic acid extraction, a one-step reverse transcription PCR assay (RT- The relatively indolent infection in our patients despite recent myelosuppression and [8] but this hypothesis requires confirmation with a truly quantitative RT-PCR assay taking into account the validity of the standard curve with reference materials or in-house plasmid controls with assigned viral copy numbers [9] before the clinical significance can be ascertained. Supporting the expert panel recommendations for disease management during the Covid-19 pandemic, [10] our report emphasizes the importance of adapting anti-cancer therapies to each patient's needs, but without undue concern about the immunosuppressive consequences of treatment. None. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York Clinical outcome of coronavirus disease 2019 in haemato-oncology patients COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study COVID-19 in persons with haematological cancers Reply to "COVID-19 in persons with haematological cancers": a focus on myeloid neoplasms and risk factors for mortality Response to "COVID-19 in persons with haematological cancers RT-PCR for SARS-CoV-2: quantitative versus qualitative Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts